RUR20kD-IL-2 Selective Treg Stimulation Dosing
Solution Overview
Problem
Current treatments for autoimmune diseases using high-dose IL-2 are limited by severe adverse events, narrow therapeutic window for Treg selectivity, and short half-life requiring frequent administration.
Innovation Solution
Development of selective Treg stimulator compositions like RUR20kD-IL-2 and rezpegaldesleukin, which are formulated and dosed to selectively promote regulatory T cell expansion and activation over conventional T cells, with improved dosing regimens to enhance therapeutic efficacy and patient compliance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high-dose IL-2 is administered to promote antitumor immune responses, then the proliferation and activity of cytotoxic lymphocytes is enhanced, but severe adverse events occur and Treg suppressive activity is decreased
Solution Approach 1:
The patent modifies IL-2 with polyethylene glycol chains of specific lengths and configurations to create localized structural differences. This results in RUR20kD-IL-2 having altered physicochemical properties that enable selective binding to Treg IL-2 receptors while excluding Tcon receptors, thus achieving local quality differentiation in receptor interaction
Solution Approach 2:
The patent systematically varies parameters including PEG chain length (20kD), degree of substitution, and molecular weight distribution of the conjugated IL-2. These parameter changes transform the original IL-2 into RUR20kD-IL-2 with extended half-life and altered receptor affinity, enabling selective Treg stimulation at low doses without activating Tcons
2Reliability
If low-dose rhIL-2 is used to selectively induce Tregs, then Treg expansion and survival are enhanced, but the therapeutic window is narrow and half-life is short requiring frequent administration
Solution Approach 1:
The polyethylene glycol conjugation creates a reservoir of drug that is slowly released from the protein structure. The PEG chains act as a sustained-release matrix, maintaining therapeutic concentrations of RUR20kD-IL-2 in circulation for extended periods, thereby achieving continuous Treg stimulation without frequent dosing
Solution Approach 2:
The patent creates a composite molecule combining IL-2 peptide with polyethylene glycol polymer chains. This composite structure integrates the biological activity of IL-2 with the pharmacokinetic benefits of PEGylation, resulting in a molecule with both Treg selectivity and extended half-life characteristics
3Reliability
If unmodified aldesleukin is used for Treg stimulation, then some Treg enhancement is achieved, but the therapeutic window is narrow and frequent dosing is required
Solution Approach 1:
The IL-2 molecule is pre-modified with polyethylene glycol chains during manufacturing to create RUR20kD-IL-2 with inherently extended half-life. This preliminary structural modification eliminates the need for frequent dosing while maintaining Treg selectivity, as the extended-circulation form is administered from the outset
Data Source
AI summary
The instant disclosure provides selective Treg stimulator compositions, including RUR20kD-IL-2 and related compositions, and rezpegaldesleukin, and formulations and dosing regimens for methods of using these compositions, for example, for treating autoimmune diseases, including atopic dermatitis.



